Epigenetic modification, such as DNA methylation (DNAm
Introduction
DNA methylation (DNAm) -an epigenetic process that can regulate gene expression -has emerged as a potential mechanism through which the genome can capture the effects of early adversity and propagate their influence [1] . The ideas of "capturing" and "propagating" summarize a mediational hypothesis: that early adversity can have long-term mental health effects (at least partially) via changes in DNAm. However, at present, very few existing studies have adopted longitudinal designs capable of testing mediation (i.e., adversity → DNAm → mental health) -hence, published "mediational" studies are rare [2] . Moreover, as these studies have focussed on living children and adolescents, they have examined DNAm from peripheral tissues (e.g. cord blood, whole blood, saliva), although brain tissue is arguably more relevant for mental health. As a result, it is not clear whether DNAm is a causal mechanism in the aetiology of mental health problems ( Fig. 1, group A) , or a biomarker, in this case a quantitative index of environmental adversity that may be independent of disease aetiology (Fig. 1, group B) . Herein, 2 recent DNAm mediation studies are reviewed, followed by a discussion of 3 key areas that could help clarify the role of DNAm in the link between adversity and mental health.
Epigenetics and DNAm
Prior to reviewing the mediation research, epigenetics and DNAm will be (briefly) defined. Epigenetic mechanisms influence dynamic changes in gene transcription independently of the genomic DNA sequence, primarily via modifications to DNA, histone proteins, and chromatin structure [3] . One of the most extensively researched epigenetic mechanisms is DNAm, which refers to the addition of a methyl group, primarily in the context of cytosine-guanine (CpG) dinucleotides [3] . In the human genome, CpG sites often cluster in CpG islands, which themselves tend to be embedded in promoter regions of genes. Methylated CpG islands impede transcription factors from accessing the DNA sequence. Increased methylation in these regions is typically associated with inhibition of gene transcription (i.e., gene silencing) and chromatin compaction. Importantly, because epigenetic processes have been shown to respond to both genetic [4] and environmental [5] influence, they represent a potential mechanism that can help explain the biology of gene-environmental interplay and disease susceptibility across the lifespan [6] .
DNAm Mediation Studies
The "promise" of a mediational framework is that -if adversity-related DNAm is a causal link in the aetiology of a mental health problem -reversing epigenetic marks might support symptom remission. Although causality has yet to be established and reduced power is an ongoing concern, research has nevertheless demonstrated that DNAm may act as a "mediator" in the link between adversity and child outcomes, and hence offer a potential target for intervention [5] . There is good evidence in animal and human studies that prenatal stress can have long- term effects on the child, such as affecting neurodevelopment. Here, vulnerability for psychiatric disorders could -in part -be due to increased exposure to cortisol and its impact on foetal brain development [7, 8] . In the first study of its kind, Monk et al. [9] examined placental DNAm as a potential pathway in the link between pregnant women's (n = 61) distress and offspring aberrant development (in utero). They reported higher perceived stress in the second trimester (24-27 gestational weeks) associated with higher methylation of HSD11B2, which is an important placental barrier gene that deactivates cortisol -a correlate of psychological stress. Higher DNAm of HSD11B2, in turn, was associated with a lower score on an index of foetal neurodevelopment, the assessment of which took place in the third trimester (34-37 weeks). The authors stated that increased DNAm of HSD11B2 can lead to the downregulation of the placental barrier enzyme, hence a pathway to elevated in utero exposure to stress-related cortisol.
In another mediation study, a "hypothesis-free" genome-wide strategy was taken. This approach allows for the discovery of novel biological correlates (as opposed to testing a priori defined candidate genes), which can aid in the development of more holistic aetiological knowledge. Here, Cecil et al. [10] , using the epidemiological birth cohort, the Avon Longitudinal Study of parents and Children, examined a subset of youth (n = 244) who were oversampled for early-onset conduct problems (i.e., before the age of 10; lying, fighting, stealing). The researchers tested epigenome-wide, prospective associations between DNAm (birth, age 7) and substance use in adolescence (tobacco, alcohol and cannabis use; age [14] [15] [16] [17] [18] . It was reported that at birth (but not at age 7), epigenetic variation across a tightly interconnected genetic network (n = 65 epigenome-wide significant loci) was associated with higher levels of substance use. Key annotated genes included PACSIN1, NEUROD4, and NTRK2, implicated in neurodevelopmental processes. In addition, prenatal maternal tobacco smoking was prospectively associated with adolescent substance use via the epigenetic variation of these 65 loci (i.e., a poly-epigenetic risk score). Of interest, several of the 65 loci were associated with known methylation quantitative trait loci [4] , which means that the levels of DNAm are likely under a degree of genetic influence. In fact, the loci that associated with methylation quantitative trait loci ("under genetic influence") showed higher continuity between birth and age 7 than the loci that were not associated with methylation quantitative trait loci ("not under genetic influence").
Discussion
Although the above studies show that DNAm can act as a mediator between risk exposure and child psychopathology, it is important to note that they are correlational in nature (non-causal). Below, 3 key areas are discussed that can help clarify the role of DNAm in the link between adversity and mental health. We note that other areas not covered here are also important, such as genetic influence, cellular heterogeneity, temporal variability, replication and functional characterization of DNAm [2, 11] .
The Issue of Peripheral Tissue as a Surrogate for Central Nervous System Function
Although the brain may be of ultimate interest, for studies on living persons, available options include collecting accessible peripheral tissues such as saliva, buccal epithelial cells, or blood. A major debate has centred on the utility of peripheral tissues for mental illnesses that primarily manifest in the brain [12] . Indeed, studies on the correlation between peripheral and CNS show mixed patterns: while a majority of CpGs do not show intraindividual association, a minority do [13] -especially those under genetic influence [14, 15] .
A strategy worth considering is to target mental health problems that have mechanistic underpinnings in other tissues, including blood [12] . Blood is a primary tissue for research focussed on immune response and peripheral inflammation [16, 17] . Indeed, a wide range of psychiatric disorders have been associated with peripheral inflammation and altered immune response [18] . Moreover, there is good evidence from animal studies, and increasing evidence in humans, that peripheral inflammatory markers can affect brain areas implicated in certain psychiatric disorders [19, 20] . Consequently, adversity-related immune processes and DNAm may be well measured in blood samples.
Candidate Gene versus Genome-Wide Strategies
Early DNAm studies, before the advent of genomewide techniques, focussed on specific candidate genes that were selected a priori, due to known functional relevance for certain mental illnesses. This strategy is best with highly targeted research questions (as in Monk et al. [9] investigating placental barrier genes). However, given the discussion directly above, a complementary approach is to not only focus on candidate genes involved in inflammatory response, but also on whole systems that functionally interrelate with immune response and brain development, such as the hypothalamic-pituitary-adre- nal axis [20] . The suggestion here is to prioritize candidate genes or systems that have plausible pathways to the CNS. Of note, several online databases catalogue known associations of DNAm between peripheral and post-mortem brain samples [14, 15] .
In recent years, genome-wide DNAm studies have become more popular, due to their increased affordability and data content [11] . The study of Cecil et al. [11] reviewed above may be an exemplar, as the top loci formed a network that was plausibly linked with neurodevelopmental risk for substance use. However, not all genomewide studies have clear-cut results. Given that intra-individual variation in a majority of the peripheral-based CpGs in genome-wide arrays tend not to co-vary with those in the brain [14, 15] , one may question whether it is worth examining these arrays in their entirety. For researchers interested in maximizing CpGs likely to associate with brain-based mental illnesses, an a priori set of CpGs (e.g., a "systems approach") could be isolated from the array data, which could still span thousands of loci [21] . Again, the suggestion is to prioritize CpGs within biological systems that are believed to associate with CNS function. An alternative approach could be to prioritize CpGs with underlying methylation quantitative trait loci, which have been validated in both peripheral and CNS tissues [14] .
Establishing DNAm as a Biomarker
Blood-based DNAm studies have shown associations with respect to both environmental adversity and mental illness [12] . One promising avenue is to establish DNAm as a biomarker for mental illness. For biomarkers to be useful, they must be cost-effective, drawn from accessible tissue and predictive of future risk [22] . One advantage of a biomarker is that it does not have to be mechanistic (i.e., CNS surrogate) (Fig. 1, group B ; see also Ladd-Acosta [22] ). Indeed, blood-based biomarkers have been used for diagnostics, predictive risk, disease monitoring and/or treatment response in cancer, cardiovascular and infectious disease [23, 24] . Although biomarkers for brainbased disorders (Alzheimer's disease, depression) have proven more difficult to establish [24] , using a genomewide approach based on blood tissues across 13 population-based cohorts, Liu et al. [25] reported that a set of 144 CpGs discriminated drinkers from non-drinkers (area under the curve: > 0.90). It was suggested that a blood-based DNAm diagnostic test could be developed to validate self-report data, in a forensic setting or as a screening test. However, as the study of Liu et al. [25] was cross-sectional, the authors noted that they could not rule out reverse causality (i.e., DNAm may be caused by alcohol intake); therefore, additional research is needed to determine whether the set of 144 CpGs could be predictive of problematic levels of future alcohol usage.
The recent interest in epigenetics, from a developmental psychopathology perspective, stems from the potential of DNAm -whether as a causal mechanism or as a biomarker -to index both exposure to adversity and vulnerability for mental health problems [2] . Toward this end, there has been substantial activity on the "epigenetics" of adversity-related disorders, such as posttraumatic stress disorder [26] and borderline personality disorder [27] . Of interest, DNAm in genes that underlie stress response, neurotransmitter activity, and immune regulation have been identified [27] . These preliminary findings may provide a useful framework for more in-depth investigations of both the pathogenesis and clinical responsiveness of these disorders. For example, if adversity affects peripheral DNAm of certain genes, which, in turn, reliably increase vulnerability for borderline personality disorder (i.e., high predictive specificity), then an efficacious intervention may also show change in both DNAm of the candidate gene and mental health symptoms for responders versus non-responders (i.e., a potential causal mechanism in symptoms). Although this area of research is in early stages, certain small-scale (proof of concept) interventions have reported joint change in DNAm of candidate genes and symptoms of mental health problems, including borderline personality [28] and anxiety [29] . Large-scale randomized controlled trials are needed to increase scientific rigour and to establish causality. Application of epigenome-wide methods [30, 31] may be especially useful for the discovery of novel biological systems that may be mechanisms -or biomarkers -of treatment response and symptom change.
